- Home
- LIFW vs COEP Comparison
LIFW vs COEP Comparison
Compare LIFW & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIFW
- COEP
- Stock Information
- Founded
- LIFW 2014
- COEP 2017
- Country
- LIFW United States
- COEP United States
- Employees
- LIFW 88
- COEP N/A
- Industry
- LIFW Computer Software: Prepackaged Software
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LIFW Technology
- COEP Health Care
- Exchange
- LIFW Nasdaq
- COEP Nasdaq
- Market Cap
- LIFW 6.2M
- COEP 7.3M
- IPO Year
- LIFW N/A
- COEP N/A
- Fundamental
- Price
- LIFW $1.94
- COEP $0.17
- Analyst Decision
- LIFW
- COEP
- Analyst Count
- LIFW 0
- COEP 0
- Target Price
- LIFW N/A
- COEP N/A
- AVG Volume (30 Days)
- LIFW 3.3M
- COEP 805.9K
- Earning Date
- LIFW 11-14-2024
- COEP 11-13-2024
- Dividend Yield
- LIFW N/A
- COEP N/A
- EPS Growth
- LIFW N/A
- COEP N/A
- EPS
- LIFW N/A
- COEP N/A
- Revenue
- LIFW $10,734,000.00
- COEP N/A
- Revenue This Year
- LIFW $293,208.70
- COEP N/A
- Revenue Next Year
- LIFW N/A
- COEP N/A
- P/E Ratio
- LIFW N/A
- COEP N/A
- Revenue Growth
- LIFW 217.86
- COEP N/A
- 52 Week Low
- LIFW $1.43
- COEP $0.15
- 52 Week High
- LIFW $82.50
- COEP $0.90
- Technical
- Relative Strength Index (RSI)
- LIFW 47.30
- COEP 60.23
- Support Level
- LIFW $1.56
- COEP $0.17
- Resistance Level
- LIFW $2.38
- COEP $0.20
- Average True Range (ATR)
- LIFW 0.47
- COEP 0.02
- MACD
- LIFW 0.05
- COEP 0.00
- Stochastic Oscillator
- LIFW 18.96
- COEP 69.05
About LIFW MSP Recovery Inc.
MSP Recovery Inc is a healthcare recovery and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services. It offers an antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions platform to recover any claims where the law places primary payment responsibility on another payer.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.